Status:
COMPLETED
Study Evaluating Bapineuzumab In Alzheimer Disease Subjects
Lead Sponsor:
Pfizer
Conditions:
Alzheimer Disease
Eligibility:
All Genders
50-89 years
Phase:
PHASE2
Brief Summary
The study will evaluate the safety and effectiveness of bapineuzumab for the treatment of mild to moderate Alzheimer disease. Subjects will be in the study for six months and will receive subcutaneous...
Eligibility Criteria
Inclusion
- Diagnosis of probable Alzheimer Disease according to National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria
- Mini-Mental State Examination (MMSE) score 16-26
Exclusion
- Magnetic Resonance Imaging (MRI) showing other brain abnormalities
- Other diagnosed neurological or psychiatric disorders
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2010
Estimated Enrollment :
79 Patients enrolled
Trial Details
Trial ID
NCT00663026
Start Date
November 1 2008
End Date
October 1 2010
Last Update
November 15 2013
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Phoenix, Arizona, United States, 85006
2
Pfizer Investigational Site
Sun City, Arizona, United States, 85351
3
Pfizer Investigational Site
Encino, California, United States, 91316
4
Pfizer Investigational Site
Los Alamitos, California, United States, 90720